A large co-operative biological and clinical study to better understand and improve treatment
of the rare t (8; 16)(p11; p13) acute myeloid leukaemia Acute myeloid leukaemia (AML) with …

In acute myeloid leukaemia (AML) t (8; 16)(p11; p13)/MYST3–CREBBP is a very rare
abnormality. Previous small series suggested poor outcome. We report on 59 patients with t …

We analyzed the hematological features and treatment outcome in 18 patients with t (8; 21)
acute myeloid leukemia (AML) diagnosed in Queen Mary Hospital, Hong Kong. They …

Clinical features and treatment outcome of 31 patients over 16 years of age with t (8; 21)
acute myeloid leukemia (AML) were compared with 60 patients without t (8; 21). Among 31 …

Abstract Translocation t (8; 16)(p11; p13) is an infrequent chromosomal abnormality in de
novo and secondary AML cases, leading to the fusion of MYST3 (MOZ) and CREBBP (CBP) …

Acute myeloid leukemia (AML) accounts for 15% cases of childhood leukemia and 80% of
leukemia in adults. Historically, outcome has been poor, with a 5-year overall survival (OS) …

The present study reviewed three patients with acute myeloid leukemia (AML) who had the
specific genetic abnormality t (16; 21)(p11; q22). To investigate the clinical and laboratory …

Introduction Acute myeloid leukemias with MLL rearrangements are frequently associated
with myelomonocytic and monoblastic/monocytic morphology, with an increased risk of …

We conducted a retrospective study to evaluate outcomes and prognostic factors of newly
diagnosed patients with t (8; 21) acute myeloid leukemia (AML). There were 70 patients (43 …

Abstract The t (8; 16)(p11; p13) is a rare translocation involved in de novo and therapy-
related myelomonocytic and monocytic acute leukemia. It fuses two genes encoding histone …